BridgeMD
New treatment option for Cancer
Official title Quality of Life and Economic Repercussions of Combining Proactive Medication Assessment and Electronic Monitoring of Toxicities in Subjects Undergoing Oral Cancer Therapy
ClinicalTrials.gov ID: NCT05345587
What this study is testing
- What it's testing
- Therapies used to treat cancer are administered orally (OT) in 75% of cases, lending themselves to outpatient care. This care pathway raises new issues: specific toxicities, drug interactions, and the relationship between the community (physicians and pharmacists) and the hospital.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patient starting oral therapy treatment in oncology for metastatic or locally advanced cancer
- Patient able to use a connected electronic object
- Patient with a smartphone/tablet or computer with internet access and an email address.
- Patient with WHO status ≤2
- Patients receiving other cancer therapy concurrently with oral therapy may be included
You likely can't join if
- The subject is participating in a category 1 treatment study, or is in a period of exclusion determined by a previous study
- The subject refuses to sign the consent
- It is impossible to give the subject informed information
- The patient is under safeguard of justice or state guardianship
- Patient pregnant, parturient or breast feeding
- Illiterate patient
See the full eligibility criteria
- Patient starting oral therapy treatment in oncology for metastatic or locally advanced cancer
- Patient able to use a connected electronic object
- Patient with a smartphone/tablet or computer with internet access and an email address.
- Patient with WHO status ≤2
- Patients receiving other cancer therapy concurrently with oral therapy may be included
- The patient must have given their free and informed consent and signed the consent form
- The patient must be a member or beneficiary of a health insurance plan
- The subject is participating in a category 1 treatment study, or is in a period of exclusion determined by a previous study
- The subject refuses to sign the consent
- It is impossible to give the subject informed information
- The patient is under safeguard of justice or state guardianship
- Patient pregnant, parturient or breast feeding
- Illiterate patient
- Patients with poor prognosis due to a serious uncontrolled medical condition, mild systemic disease, uncontrolled infection (cardiac, pulmonary, renal, etc.)
- Patient receiving hormone therapy alone for breast or prostate cancer
The study team makes the final eligibility decision.
Where it's taking place
- Brive-la-Gaillarde, France
- Castres, France
- Le Puy-en-Velay, France
- Nîmes, France
- Villeurbanne, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Brive-la-Gaillarde, France; Castres, France; Le Puy-en-Velay, France; Nîmes, France; Villeurbanne, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.